KR102715157B1 - Il-17c에 대한 항체 - Google Patents

Il-17c에 대한 항체 Download PDF

Info

Publication number
KR102715157B1
KR102715157B1 KR1020187024953A KR20187024953A KR102715157B1 KR 102715157 B1 KR102715157 B1 KR 102715157B1 KR 1020187024953 A KR1020187024953 A KR 1020187024953A KR 20187024953 A KR20187024953 A KR 20187024953A KR 102715157 B1 KR102715157 B1 KR 102715157B1
Authority
KR
South Korea
Prior art keywords
seq
antibody
leu
ser
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187024953A
Other languages
English (en)
Korean (ko)
Other versions
KR20180109977A (ko
Inventor
얀 도미니크 하아스
위르겐 클라틱
닉 에르네스트 르네 반데그힌스테
Original Assignee
모르포시스 아게
갈라파고스 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 모르포시스 아게, 갈라파고스 엔.브이. filed Critical 모르포시스 아게
Publication of KR20180109977A publication Critical patent/KR20180109977A/ko
Application granted granted Critical
Publication of KR102715157B1 publication Critical patent/KR102715157B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020187024953A 2016-02-19 2017-02-17 Il-17c에 대한 항체 Active KR102715157B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16156582.5 2016-02-19
EP16156582 2016-02-19
EP16156651.8 2016-02-22
EP16156651 2016-02-22
PCT/EP2017/053592 WO2017140831A1 (en) 2016-02-19 2017-02-17 Antibodies for il-17c

Publications (2)

Publication Number Publication Date
KR20180109977A KR20180109977A (ko) 2018-10-08
KR102715157B1 true KR102715157B1 (ko) 2024-10-10

Family

ID=58057136

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020187024953A Active KR102715157B1 (ko) 2016-02-19 2017-02-17 Il-17c에 대한 항체

Country Status (33)

Country Link
US (5) US20190048071A1 (https=)
EP (1) EP3416983B1 (https=)
JP (2) JP6535139B2 (https=)
KR (1) KR102715157B1 (https=)
CN (1) CN108699143B (https=)
AU (1) AU2017219837B2 (https=)
BR (1) BR112018016798A2 (https=)
CA (1) CA3014842A1 (https=)
CL (1) CL2018002340A1 (https=)
CO (1) CO2018008724A2 (https=)
CU (1) CU20180087A7 (https=)
CY (1) CY1124296T1 (https=)
DK (1) DK3416983T3 (https=)
EA (1) EA037813B1 (https=)
EC (1) ECSP18070641A (https=)
ES (1) ES2877376T3 (https=)
HR (1) HRP20211059T1 (https=)
HU (1) HUE054755T2 (https=)
IL (1) IL260733B2 (https=)
LT (1) LT3416983T (https=)
MA (2) MA44227B1 (https=)
MD (1) MD3416983T2 (https=)
MX (1) MX2018009860A (https=)
PH (1) PH12018501739A1 (https=)
PL (1) PL3416983T3 (https=)
RS (1) RS62012B1 (https=)
SG (1) SG11201806161TA (https=)
SI (1) SI3416983T1 (https=)
SM (1) SMT202100361T1 (https=)
TN (1) TN2018000289A1 (https=)
TW (1) TW201734041A (https=)
WO (1) WO2017140831A1 (https=)
ZA (1) ZA201806249B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10604566B2 (en) * 2015-10-05 2020-03-31 Galapagos Nv Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
HRP20211059T1 (hr) * 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c
TW201919698A (zh) * 2017-09-25 2019-06-01 德商莫菲西斯公司 異位性皮炎之治療
GB201803563D0 (en) 2018-03-06 2018-04-18 Galapagos Nv Antibodies and pharmaceutical compositions thereof for the treatment of autoimmune skin diseases
TW202011995A (zh) * 2018-07-03 2020-04-01 比利時商葛萊伯格有限公司 高濃度液體抗體配製物
IL292940A (en) * 2019-11-22 2022-07-01 Morphosys Ag Collection of extractant during antibody chromatography
EP4061825A1 (en) * 2019-11-22 2022-09-28 MorphoSys AG Method to increase antibody yield during ion exchange chromatography

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
WO2013057241A1 (en) * 2011-10-19 2013-04-25 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247080A (en) 1983-03-08 1988-12-20 Commonwealth Serum Laboratories Commission Antigenically active amino acid sequences
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7771951B2 (en) 2001-12-03 2010-08-10 Amgen Fremont Inc. Antibody categorization based on binding characteristics
AU2005295421A1 (en) 2004-10-18 2006-04-27 Zymogenetics, Inc. Soluble Zcytor21, anti-Zcytor21 antibodies and binding partners and methods of using in inflammation
US20070129302A1 (en) * 2005-10-18 2007-06-07 Zeren Gao Il-17c antagonists and methods of using the same
EP2064237A2 (en) 2006-10-18 2009-06-03 ZymoGenetics, Inc. Il-17c antagonists and methods of using the same
US8367586B2 (en) 2010-11-19 2013-02-05 Morphosys Ag Collection and methods for its use
WO2013016220A1 (en) 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
JP2015521591A (ja) * 2012-06-12 2015-07-30 オレガ・バイオテック Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用
EP3233915B1 (en) * 2014-12-15 2024-08-28 MorphoSys AG Antibodies for il-17c
HRP20211059T1 (hr) 2016-02-19 2021-10-01 Morphosys Ag Antitijela za il-17c

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999060127A2 (en) 1998-05-15 1999-11-25 Genentech, Inc. Il-17 homologous polypeptides and therapeutic uses thereof
US20120201821A1 (en) 2010-10-25 2012-08-09 Gonzalez Jr Lino Treatment of Gastrointestinal Inflammation and Psoriasis and Asthma
WO2013057241A1 (en) * 2011-10-19 2013-04-25 Morphosys Ag Antagonists of il17c for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
KR20180109977A (ko) 2018-10-08
JP2019511910A (ja) 2019-05-09
RS62012B1 (sr) 2021-07-30
CN108699143B (zh) 2021-11-09
MX2018009860A (es) 2019-03-28
WO2017140831A1 (en) 2017-08-24
LT3416983T (lt) 2021-07-12
ECSP18070641A (es) 2018-10-31
CN108699143A (zh) 2018-10-23
CU20180087A7 (es) 2019-03-04
US20190202906A1 (en) 2019-07-04
MA44227B1 (fr) 2021-06-30
IL260733B2 (en) 2024-03-01
US10633439B2 (en) 2020-04-28
US10259869B2 (en) 2019-04-16
MA44227A (fr) 2018-12-26
SMT202100361T1 (it) 2021-07-12
EA201891594A1 (ru) 2019-01-31
EP3416983B1 (en) 2021-04-07
US20250074978A1 (en) 2025-03-06
EP3416983A1 (en) 2018-12-26
JP6535139B2 (ja) 2019-06-26
IL260733B1 (en) 2023-11-01
DK3416983T3 (en) 2021-06-21
MD3416983T2 (ro) 2021-08-31
CL2018002340A1 (es) 2018-11-23
CY1124296T1 (el) 2022-11-25
TN2018000289A1 (en) 2020-01-16
PL3416983T3 (pl) 2021-10-25
SG11201806161TA (en) 2018-08-30
JP2019162119A (ja) 2019-09-26
CO2018008724A2 (es) 2018-08-31
ES2877376T3 (es) 2021-11-16
AU2017219837B2 (en) 2023-08-17
US11987621B2 (en) 2024-05-21
BR112018016798A2 (en) 2018-12-26
IL260733A (https=) 2018-09-20
HUE054755T2 (hu) 2021-09-28
PH12018501739A1 (en) 2019-06-10
MA43088B1 (fr) 2020-10-28
ZA201806249B (en) 2020-02-26
MA43088A1 (fr) 2019-05-31
SI3416983T1 (sl) 2021-08-31
HRP20211059T1 (hr) 2021-10-01
JP6916834B2 (ja) 2021-08-11
EA037813B1 (ru) 2021-05-24
US20190048071A1 (en) 2019-02-14
CA3014842A1 (en) 2017-08-24
TW201734041A (zh) 2017-10-01
US20180340024A1 (en) 2018-11-29
US20200216529A1 (en) 2020-07-09
AU2017219837A1 (en) 2018-08-09

Similar Documents

Publication Publication Date Title
KR102715157B1 (ko) Il-17c에 대한 항체
MX2014004662A (es) Antagonistas de il17c para el tratamiento de trastornos inlflamatorios.
KR102562418B1 (ko) 항-테나신 c 항체 및 이의 용도
JP2025506143A (ja) 多重特異性結合性作用剤およびその使用
CA3124356A1 (en) Fn14 antibodies and uses thereof
US10604566B2 (en) Antagonists of IL-17C for the treatment and/or prevention of atopic dermatitis
KR20240049304A (ko) 융합 단백질을 함유하는 약학적 조성물
CN115916821A (zh) 用于疫苗接种和感染性疾病的治疗的组合物和方法
HK1259711B (en) Antibodies for il-17c
HK1259711A1 (en) Antibodies for il-17c
CN118974098A (zh) 多重特异性结合剂及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R11-asn-PN2301

St.27 status event code: A-3-3-R10-R13-asn-PN2301

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

St.27 status event code: A-5-5-R10-R13-asn-PN2301